Literature DB >> 11348527

The situation of sleeping sickness in Angola: a calamity.

A Stanghellini1, T Josenando.   

Abstract

Although nearly one-fifth of the Angolan population is at risk of becoming infected with trypanosomiasis, only 6% currently have access to surveillance and treatment because of the war and its resultant destruction of the country's infrastructure. The paper outlines the history of human African trypanosomiasis (HAT) control activities in Angola and sums up what measures need to be taken to re-establish them.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11348527     DOI： 10.1046/j.1365-3156.2001.00724.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN： 1360-2276            Impact factor:   2.622


  25 in total

1.  African Trypanosomiasis: Changing Epidemiology and Consequences.

Authors:  Jean-Paul Chretien; Bonnie L Smoak
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 2.  Options for field diagnosis of human african trypanosomiasis.

Authors:  François Chappuis; Louis Loutan; Pere Simarro; Veerle Lejon; Philippe Büscher
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies.

Authors:  Walter O Inojosa; Inacio Augusto; Zeno Bisoffi; Teofile Josenado; Paulo M Abel; August Stich; Christopher J M Whitty
Journal:  BMJ       Date:  2006-06-15

4.  Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.

Authors:  Marcel Kaiser; Michael A Bray; Monica Cal; Bernadette Bourdin Trunz; Els Torreele; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

5.  Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice.

Authors:  Patient Pati Pyana; Ipos Ngay Lukusa; Dieudonné Mumba Ngoyi; Nick Van Reet; Marcel Kaiser; Stomy Karhemere Bin Shamamba; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2011-04-19

6.  The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes.

Authors:  Harry P de Koning; Laura F Anderson; Mhairi Stewart; Richard J S Burchmore; Lynsey J M Wallace; Michael P Barrett
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  The epidemiology of trypanosomiasis in Rumphi district, Malawi: a ten year retrospective study.

Authors:  Mwayiwawo Madanitsa; John Chisi; Bagrey Ngwira
Journal:  Malawi Med J       Date:  2009-03       Impact factor: 0.875

Review 8.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

9.  Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.

Authors:  Gerardo Priotto; Loretxu Pinoges; Isaac Badi Fursa; Barbara Burke; Nathalie Nicolay; Guillaume Grillet; Cathy Hewison; Manica Balasegaram
Journal:  BMJ       Date:  2008-03-05

10.  Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness.

Authors:  Irene Kuepfer; Caecilia Schmid; Mpairwe Allan; Andrew Edielu; Emma P Haary; Abbas Kakembo; Stafford Kibona; Johannes Blum; Christian Burri
Journal:  PLoS Negl Trop Dis       Date:  2012-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.